Journal Mobile Options
Table of Contents
Vol. 120, No. 1, 2008
Issue release date: October 2008
Acta Haematol 2008;120:36–46

Post-Transplant Lymphoproliferative Disorders after Heart or Kidney Transplantation at a Single Centre: Presentation and Response to Treatment

Aversa S.M.L. · Stragliotto S. · Marino D. · Calabrese F. · Rigotti P. · Marchini F. · Gambino A. · Feltrin G. · Boso C. · Canova F. · Soldà C. · Mazzarotto R. · Burra P.
aDivision of Medical Oncology and bDepartment of Radiotherapy, Istituto Oncologico Veneto, IRCCS, cDepartment of Medical Sciences and Special Therapies, dKidney and Pancreas Transplantation Unit, Department of Medical and Surgical Sciences, eDepartment of Cardiothoracic Sciences and fDepartment of Surgical and Gastroenterological Science, University of Padua, Padua, Italy

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Post-transplant lymphoproliferative disorders (PTLD) is a serious complication after solid organ transplantation. Reduction of immunosuppression (RI) alone is not able to control the disease. We report a prospective analysis of 30 patients with PTLD after heart or kidney transplantation. Only 5 of 30 patients, treated solely with RI, obtained a complete response. Five patients were treated heterogeneously; in the remaining 20, the efficacy and safety of a weekly anthracycline-based chemotherapy were assessed. Sixteen patients obtained a complete remission. One death was related to treatment. With a median follow-up of 36 months, 3-year overall survival was 63.3% and 57% for the entire group and the chemotherapy-treated group, respectively. Moreover, 4 second neoplasms were observed in the chemotherapeutic group. In this study, we demonstrated that most PTLD need other treatment than RI and a weekly regimen is manageable and has a favourable impact on long-term survival.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Feng S, Buell JF, Chari RS, DiMaio JM, Hanto DW: Tumors and transplantation: the 2003 Third Annual ASTS State-of-the-Art Winter Symposium. Am J Transplant 2003;3:1481–1487.
  2. Opelz G, Dohler B: Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4:222–230.
  3. Taylor AL, Marcus R, Bradley JA: Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Oncology 2005;56:155–167.
  4. Penn I: The role of immunosuppression in lymphoma formation. Springer Semin Immunopathol 1998;20:343–353.
  5. Gao S, Chapparo SV, Perlroth M, Montoya JG, Miller JL, DiMiceli S, Hastie T, Oyer PE, Schroeder J: Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 2003;22:505–514.
  6. Wasson S, Zafar MN, Best J, Reddy HK: Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-centre experience. J Cardiovasc Pharmacol Ther 2006;11:77–83.
  7. Liebowitz D: Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998;338:1413–1421.
  8. Markin RS, Wood RP, Shaw BW Jr, Brichacek B, Purtilo DT: Immunohistologic identification of Epstein-Barr virus induced hepatitis reactivation after OKT-3 therapy following orthotopic liver transplant. Am J Gastroenterol 1990;85:1014–1018.
  9. Opelz G, Henderson R: Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514–1516.
  10. Birkeland SA : Cancer in cadaveric kidney transplant patients. Surgery 1983;93:504–507.
  11. Cockfield SM: Identifying the patient at risk for post-transplantation lymphoproliferative disorder. Transplant Infect Dis 2001;3:70–78.
  12. Burra P, Buda A, Livi U, Rigotti P, Zanus G, Calabrese F, Caforio A, Menin C, Canova D, Farinati F, Aversa SM : Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection? Eur J Gastroenterol Hepatol 2006;18:1065–1070.
  13. Duvoux C, Pageaux GP, Vanlemmens C, Thoraval FR, Rolland ALV, Hezode C, Gaulard P, Miguet JP, Larrey D, Dhumeaux D, Cherqui D: Risk factors for lymphoproliferative disorders after liver transplantation in adults: analysis of 480 patients. Transplantation 2002;74:1103–1109.
  14. Hezode C, Duvoux C, Germanidis G, Roudot-Throraval F, Vincens AL, Gaulard P, Cherqui D, Pawlotsky JM, Dhumeaux D: Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation. Hepatology 1999;30:775–778.
  15. Gerritsen EJ, Stam ED, Hermans J, van den Berg H, Haraldsson A, van Tol MJ, van den Bergh RL, Waaijer JL, Kroes AC, Kluin PM, Vossen JM: Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant 1996;18:377.
  16. Harris NL, Swerdlow SH, Frizzera G: Post-transplant lymphoproliferative disorders; in Jaffe ES, Harris NL, Stein H, Vardlman JW (eds): World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001, pp 264–269.
  17. Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L, Gandjbakhch I, Binet JL, Raphael M: Post-transplantation lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998;6:2052–2059.
  18. Armitage JM, Kormos RL, Stuart RS, Fricker FJ, Griffith BP, Nalesnik M, Hardesty M, Dummer JS: Post transplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression: J Heart Lung Transplant 1991;10:877–886; discussion 886–887.
  19. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI: Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995;86:3333–3340.
  20. Cesarman E, Chadburn A, Liu YF, Migliazza A, Dalla-Favera R, Knowles DM: BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 1998;92:2294–2302.
  21. Nalesnik MA, Makowka L, Starzl TE: The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988;25:367–472.
  22. Dotti G, Fiocchi R, Motta T, Mammana C, Gotti E, Riva S, Cornelli P, Viero P, Oldani E, Ferrazzi P, Remuzzi G, Barbui T, Rambaldi A: Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation 2002;74:1095–1102.
  23. Mamzer-Bruneel MF, Lome C, Morelon E, Levy V, Bourquelot P, Jacobs F, Gessain A, Mac Intyre E, Brousse N, Kreis H, Hermine O: Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphproliferation: a report of 16 cases observed in a single centre. J Clin Oncol 2000;18:3622–3632.
  24. Norin S, Kimby E, Ericzon BG, Christensson B, Sander B, Soderdahl G, Haglund H: Post-transplant lymphoma: a single experience of 500 liver transplantations. Med Oncol 2004;21:273–384.
  25. Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC, Olthof KM, Schuster SJ, Nesta SD, Stadtmauer EA, Tsai DF: Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006;6:569–576.
  26. Trappe R, Choquet S, LeBlond V, Papp-Vary M, Riess H: Sequential treatment with the anti-CD20 antibody rituximab and CHOP+GCSF chemotherapy in patients with post-transplant lymphoproliferative disorder (PTLD): first results of a multicenter phase II study. Blood 2005;106:932–937.
  27. Choquet S, Trappe R, Leblond V, Jager U, Davi F, Oertel S: CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007;92:273–274.
  28. Mielpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot B, Requerre Y, Stoppa AM, Bourquard P, Hurault de Ligny B, Dubief F, Matieu-Boue A, Leblond V: Humanized anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000;11(suppl 1):113–116.
  29. Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandeberghe P, Fischer A, Morschauer F, salles G, Feremans W, Vilmer F, Peraldi Mn, Lang P, Lebraunchu Y, Oksenhendler E, Garnier JL, Lay T, Jaccard A, Offner f, Hermie O, Moreau A, Fafi-Kremer S, Morand P, Chatenoud L, Berrio-Varoqueaux N, Bergougnoux L, Milpied N: Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006;107:3053–3057.
  30. Trappe R, Riess H, Babel N, Kummel M, Lehmkuhl H, Jonas S, Anagnostopoulos I, Papp-Vary M, Reinke P, Hetzer R, Dorken B, Oertel S: Chemotherapy for refractory and relapsed post-transplant lymphoproliferative disorders (PTLD) after treatment with a single-agent rituximab. Transplantation 2007;83:912–918.
  31. Cheson BD, Horning SJ, Coiffier B, Shiff MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippesten D, Hiddeman W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Cannellos GP: Report of an International workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 1999;17:1244–1253.
  32. Bindl JM, Warnke RA: Advantages of detecting monoclonal antibody binding to tissue sections with biotin and avidin reagents in Coplin jars. Am J Clin Pathol 1986;85:490–493.
  33. Ganzina F: 4’-Epi-doxorubicin, a new analogue of doxorubicin. A preliminary overview of preclinical and clinical data. Cancer Treat Rev 1983;10:1–22.
  34. O’Reilly SEM, Hoskins P, Klimo P, O’ Conors JM: MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin’s disease. Ann Oncol 1991;2(suppl 1):17–23.

    External Resources

  35. Olivieri A, Santini G, Patti C, Chisesi T, De Souza C, Rubagotti A, Aversa S, Bilio A, Porcellini A, Candela M, Centurioni R, Congiu AM, Brunori AM, Nati S, Spriano M, Vimercati M, Marino G, Contu A, Tedeschi L, Maiolino I, Crugnolo M, Sertoli MR: Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin’s lymphoma: long-term results by the NHLCSG. Ann Oncol 2005;16:1941–1948.
  36. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA: Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 2002;20:630–637.
  37. Ghobrial IM, Habermann TM, Macon WR, Ristow KM, Larson TS, Walker RC, Ansell SM, Gores GJ, Stegall MD, McGregor CG: Differences between early and late post transplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation 2005;79:244–247.
  38. Bower M: The management of lymphoma in the immunosuppressed patient. Best Pract Res Clin Haematol 2002;15:517–532.
  39. Taylor AL, Bowles KM, Callaghan CJ, Wimperis JZ, Grant JW, Marcus RE, Bradley JA: Anthracycline-based chemotherapy as first-line treatment in adults with malignant post transplant lymphoproliferative disorder after solid organ transplantation. Transplantation 2006;82:375–381.
  40. Fohrer C, Caillard S, Koumarianou A, Ellero B, Woehl-Jaegle ML, Meyer C: Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. Br J Haematol 2006;134:602–612.
  41. Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D’Avanzo G, Comoli P, Baldanti F,Montillo M, Nosari A, Morra E, Cooperative Study Group on PTLD: Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica 2002;87:67–77.
  42. Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langas AN, McDonald RA, Ryckman FC, Saw BW, Sudan DL, Lynch JC: Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005;23:6481–6488.
  43. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, Lo Buglio A, Jonas C, Klippenstein D, Dallaire B, Varns C: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti CD-20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol1999;17:268–276.
  44. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
  45. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermè C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coifier B: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117–4126.
  46. Fay A, Van Den Abeele T, Peuchmaur M, Mathieu-Boue A, Vilmer E: Anti CD-20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet 1998;352:1285.
  47. Svoboda J, Kotloff R and Tsai DE: Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Transpl Int 2006;19:259–269.
  48. Orjuela M, Gross TG, Cheung Y, Alobeid B, Morris E, Cairo MS: A pilot study of chemoimmunotherapy (cyclophosfamide, prednisone, and rituximab) in patients with post-transplant lymphopolipherative disorder following solid organ transplantation. Clin Cancer Res 2003;9(suppl):3945s–3952s.
  49. Buadi F, Heyeman MR, Gocke C, Rapaport A, Hakimian R, Bartlett S, Sarkoodee-Adoo C: Treatment and outcome of post-transplant lymphoproliferative disease: a single institution study. Am J Hematol 2007;82:208–214.
  50. Patel H, Vogl DT, Aqui N, Shaked A, Olthoff K, Markmann J, Reddy R, Stadtmauer EA, Schuster S, Tsai DE: Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases. Leuk Lymphoma 2007;48:885–891.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50